Targeting a tumor-specific epitope on podocalyxin increases survival in human tumor preclinical models

HIGHLIGHTS

• who: Diana Canals Hernaez from the Shanxi Datong University, China have published the paper: Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models, in the Journal: (JOURNAL)
• what: The authors evaluate the ability of PODO447 to serve as the targeting arm for therapeutic drug delivery in ADC assays. The authors provide key proof-of-concept data that PODO447-ADCs are effective in_vivo and provide longterm tumor clearance in two immunodeficient animal models.
• how: The authors examined the effectiveness of PODO447-ADC in a second human tumor xenograft model . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.